Fatih M. Uckun, M.D., Ph.D, is an Active Member of the American Society for Clinical Investigation (ASCI), an honor society for physician-scientists, and an active member of several professional organizations, including ASCO and AACR. He earned his doctoral degrees at University of Heidelberg in Germany and completed his residency training in Pediatrics, fellowship training in Hematology/Oncology/Blood and Bone Marrow Stem Cell Transplantation, as well as postdoctoral research training in immunology at the University of Minnesota in the US. Dr. Uckun has more than 30 years of professional experience in developmental therapeutics and biopharmaceuticals. Dr. Uckun worked as a Professor of Therapeutic Radiology-Radiation Oncology, Pharmacology, and Pediatrics as well as Director of the Biotherapy Institute at the University of Minnesota (1986-1997), where he became the first recipient of the Endowed Hughes Chair in Biotherapy, and as a Professor of Pediatrics and Head of Translational Research in Leukemia and Lymphoma of the Children’s Center for Cancer and Blood Diseases at the University of Southern California (2009-2015). He has held executive positions in multiple biotechnology companies and has extensive relevant regulatory experience. In particular, he served as the IND-sponsor for experimental drugs and biologics. He has published more than 500 peer-reviewed papers and he has authored numerous review articles and book chapters. He received numerous awards including the Stohlman Memorial Award of the Leukemia Society of America (now known as the Leukemia and Lymphoma Society/LLS), the highest honor given to a Leukemia Society Scholar. He has served as a member of several editorial boards and NIH grant review/special emphasis panels.
Joan-Lluis Vives Corrons is a Professor of Medicine (1976-present) and Head of the Red Blood Cell Pathology Unit (1997 –present) at the Hospital Clínic i Provincial (University of Barcelona), with main activity focused on the diagnosis of RBC defects and in the identification of low prevalence anaemias or “Rare Anaemias”.Research has mainly based on physiopathology, molecular mechanisms and epidemiology of red blood cell (RBC) disorders due to hereditary enzymopathies (G6PD, PK and others), haemoglobinopathies (Sickle-cell anaemia and thalassaemias) and membrane defects (hereditary spherocytosis elliptocytosis and stomatocytosis).Scientific Trajectory is guaranteed by 326 publications in scientific journals, the participation (as editor or collaborator) in about 25 books of haematology, and by the accomplishment of 43 funded research projects, which have been partially funded by different public health organizations from Spain (Ministry of Health and Education and Science), Catalan Government and European Commission.Since 2002, Dr. Vives is head of the Project ENERCA (European Network for Rare and Congenital Anaemias) funded by the European Commission – Executive Agency for Health and Consumers (EAHC). ENERCA intends to contribute to the better knowledge of rare anaemias in Europe, its faster diagnosis, treatment; and epidemiological surveillance (www.enerca.org). Its final objective is the consolidation of a European Reference Network (ERN) of Expert Centres in Rare Anaemias (RA).
Dr.Martin Herrmann first studied chemistry in Würzburg and Erlangen. He then completed his studies in biology at the Friedrich-Alexander-University Erlangen in July 1983 with a diploma. After graduating from the Department of Clinical Immunology and Rheumatology of FAU Erlangen in 1989, he was hired as a post-doc in this department and a one-year study abroad at the University of Alabama, Birmingham, USA. As a result of his habilitation in December 1997, Herrmann was a Privatdozent at the Institute for Clinical Immunology and Rheumatology of the FAU Erlangen and was later appointed as an unscheduled professor. Since his diploma thesis Herrmann has been dealing with a certain type of autoimmune disease , systemic lupus erythematosus ( SLE ). Since then he has worked in projects and collaborations in research in the field of immunology and especially in the research of SLE.
A new systems approach to diseased states and wellness result in a new branch in the healthcare services, namely, personalized & precision medicine (PPM). To achieve the implementation of PPM concept, it is necessary to create a fundamentally new strategy based upon the subclinical and predictive recognition of biomarkers of hidden abnormalities long before the disease clinically manifests itself. Each decision-maker values the impact of their decision to use PPM on their own budget and well-being, which may not necessarily be optimal for society as a whole. It would be extremely useful to integrate data harvesting from different databanks and from different periods of the individual life (including family planning and childhood to get the cancer risks minimized) for applications such as prediction and personalization of further canonical treatment and preventive-prophylactic manipulations to thus provide more tailored measures for the patients and persons-at-risk resulting in improved outcomes, reduced adverse events, and more cost effective use of health care resources. A lack of medical guidelines has been identified by the majority of responders as the predominant barrier for adoption, indicating a need for the development of best practices and guidelines to support the implementation of PPM into daily practice of practitioners including oncologists of the next-step generations! PPM as being the Grand Challenge to forecast, to predict and to prevent is rooted in a big and a new science generated by the achievements of systems biology and translational Medicine (TM). NIH (Bethesda, USA) has included PPM into a List of The Greatest Priorities in XXI Century. Implementation of PPM requires a lot before the current model “physician-patient” could be gradually displaced by a new model “medical advisor-healthy person-at-risk”. This is the reason for developing global scientific, clinical, social, and educational projects in the area of PPM to elicit the content of the new branch.
Sergey Suchkov was born in the City of Astrakhan, Russia, in a family of dynasty medical doctors. In 1980, graduated from Astrakhan State Med University and was awarded with MD. In 1985, maintained his PhD as a PhD student of the I.M. Sechenov Moscow Medical Academy and Inst of Med Enzymology. In 2001, maintained his Doctor Degree at the Nat Inst of Immunology, Russia. From 1989 through 1995, was being a Head of the Lab of Clin Immunology, Helmholtz Eye Research Inst in Moscow. From 1995 through 2004 - a Chair of the Dept for Clin Immunology, Moscow Clinical Research Institute (MONIKI). In 1993-1996, was a Secretary-in-Chief of the Edit Board, Biomedical Science, an int journal published jointly by the USSR Academy of Sciences and the Royal Society of Chemistry, UK. At present, Dr Sergey Suchkov, MD, PhD, is Professor, Director, Center for Personalized Medicine, Sechenov University and Dept of Clinical Immunology, A.I.Evdokimov Moscow State Medical and Dental University; Professor, Chair, Dept for Translational Medicine, Moscow Engineering Physical Institute (MEPhI), Russia; Secretary General, United Cultural Convention (UCC), Cambridge, UK. Dr Suchkov is a member of the New York Academy of Sciences, USA; American Chemical Society (ACS), USA
Claudio Dario Dufour received a medical degree from the University of Buenos Aires, Argentina and completed his Internal Medicine Residency at the University of Buenos Aires Associated Bernardo Houssay Hospital of Vicente Lï¿½pez, Buenos Aires. Dr. Dufour currently serves as Associate Professor of Medicine & Haematology at the Univ. of Buenos Aires, School of Medicine. Dr. Dufour holds membership in several professional societies: European Hematology Association (EHA), American Association of Blood Banks (AABB) and International Society of Cellular Therapy (ISCT). He has done a two Masters: Health Management at Dr. Favaloro s University, Argentina - 2010, and Stem Cell Transplantation at University of Valencia, Spain, 2015-2016. Dr. Dufour was elected as the 2014 winner at the Short Term Visiting Award of the EHA, scholarship where he developed skills in Stem cell Transplantation and Oncohematology. He is an active honorary collaborator at AABB, working as International Cell Therapy Ambassador for Latin America (2015 ï¿½ 2018), and as Cell Therapy Assessor since 2012 up nowadays. He has done many trainees abroad in Stem Cell Transplantion: University of California (UCI) 1995; N. York Cord Blood Bank 2002, Barcelona Banc de Sang i Teixits 2005; LifeBank Vancouver, Canada 2011. Dr. Dufour has activities in Quality Management programs as ISO 9001 internal auditor for Bureau Veritas Argentina, and he has activities as Advisor in Cell Therapy in Argentina. His areas of interest include stem cell transplantation, cell therapies and regenerative medicine, multiple myeloma, the biology of plasma cells, new drug development, and special focus on pre & pos grade Educational Activities.